Editorial Comment

Journal of Urology

Volumn 182, Issue 3, 2009, Pages 947-948

  Bander, Neil H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; BASAL CELL; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TIGHT JUNCTION;

EID: 68149165765     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.05.131     Document Type: Note

References (6)

1. Troyer J.K., Beckett M.L., and Wright G.L. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30 (1997) 232
2. Liu H., Moy P., Kim S., et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57 (1997) 3629
3. Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60 (2000) 5237
4. Smith-Jones P.M., Vallabhajosula S., Navarro V., et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 44 (2003) 610
5. Milowsky M.I., Nanus D.M., Kostaglou L., et al. Phase I trial of 90Y-labeled anti-PSMA monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2522
6. Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591